Comparison of the second-line treatments for patients with small cell lung cancer sensitive to previous platinum-based chemotherapy: A systematic review and Bayesian network analysis

Shi, Hongmei; Guo, Nuojin; Zhang, Zhao; Liu, Ligang; Ni, Tianyi; Zhang, Jinye; Lu, Yunhu

doi:10.3389/fonc.2023.1154685

Cited by 4 publications

(4 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This finding is consisting with previous reports in patients with smallcell lung cancer, which is classified as NEC according to the World Health Organization (WHO) classification [17]. The nature of NEC and of small-cell lung cancer is considered to be similar, suggesting that second-line platinum and etoposide combination therapy in the present study exhibited shorter PFS and OS compared to first-line therapy, similar to findings in small-cell lung cancer [18].…”

Section: Discussionsupporting

confidence: 91%

Comparison of Efficacy and Safety between Carboplatin-Etoposide and Cisplatin-Etoposide Combination Therapy in Patients with Advanced Neuroendocrine Carcinoma: A Retrospective Study

Imai,

Saijo,

Kawamura

et al. 2023

Oncology

View full text Add to dashboard Cite

Introduction: Neuroendocrine carcinoma (NEC) is characterized by a poor prognosis and is generally treated with platinum and etoposide combination therapy as first-line chemotherapy. However, it remains uncertain whether carboplatin and etoposide combination therapy (CE) and cisplatin and etoposide combination therapy (PE) have comparable treatment efficacy. In this retrospective analysis, we compared the efficacy and safety of CE and PE in patients with NEC. Methods: We retrospectively reviewed the patient’s clinical record from 2005 to 2022 at the Department of Medical Oncology, Tohoku University Hospital. Patients who received either CE or PE were included in the study. Statistical analyses were performed using JMP Pro 16.0 (SAS Institute Inc., Cary, N.C., USA). Results: A total of 104 patients were enrolled, with 73 patients assigned to the CE group and 31 patients assigned to the PE group. Statistically, the response rate, progression-free survival (PFS) time and overall survival (OS) time were 42.6%, 5.1 months (95%CI: 3.5–6.3) and 13.6 months (95%CI: 8.9–17.4), respectively, in the CE groups and 44.4%, 5.6 months (95%CI: 3.1–7.0) and 12.5 months (95%CI: 11.2–14.6), respectively, in the PE groups. There was no significant difference in treatment efficacy between the CE and the PE groups. However, the number of patients with elevated creatinine (3.35 mg/dl and 3.88 mg/dl in two patients, respectively) was significantly higher in the PE group than in the CE group. Conclusion: The efficacy of CE and PE in patients with NEC is comparable. However, the incidence of renal dysfunction was found to be significantly higher in the PE group than in the CE group.

show abstract

Section: Discussionsupporting

confidence: 91%

Comparison of Efficacy and Safety between Carboplatin-Etoposide and Cisplatin-Etoposide Combination Therapy in Patients with Advanced Neuroendocrine Carcinoma: A Retrospective Study

Imai,

Saijo,

Kawamura

et al. 2023

Oncology

View full text Add to dashboard Cite

show abstract

“…AMR monotherapy has been established as a second‐line chemotherapy regimen in patients with SCLC. 4 A phase‐3 trial evaluating the efficacy of AMR in SCLC reported OS and PFS of 7.5 and 4.1 months, respectively. 10 The most common adverse effect associated with AMR is neutropenia, which can be managed with filgrastim.…”

Section: Discussionmentioning

confidence: 99%

“…Although several ICIs are widely used, and preferred regimens for primary therapy of extensive‐stage SCLC that include ICIs are constantly evolving, the optimal second‐line therapy for SCLC remains unclear. 3 AMR, an inhibitor of DNA topoisomerase II, is considered one of the most effective second‐line agents for SCLC, 4 with some studies reporting the efficacy of second‐line AMR for relapsed SCLC. 5 , 6 Nevertheless, prior to 2023, only two case reports had been published regarding the utilization of AMR for metastatic SCBC.…”

Section: Introductionmentioning

confidence: 99%

Metastatic small cell bladder cancer treated with sequential systemic therapy including pembrolizumab and amrubicin: A case report

Mitani,

Tsuboi,

Tanaka

et al. 2023

IJU Case Reports

View full text Add to dashboard Cite

IntroductionSmall cell bladder cancer is a relatively rare tumor, representing <1% of all bladder tumors. Amrubicin monotherapy is used as second‐line treatment for small cell lung cancer in Japan.Case presentationA 79‐year‐old woman presented with gross hematuria and was diagnosed with small cell bladder cancer (T2 or higher). Neoadjuvant chemotherapy with etoposide and cisplatin resulted in a partial response. Robot‐assisted radical cystectomy was performed, and radical resection was achieved. As we identified metastasis in the pleura 1 year later, we administered carboplatin and etoposide, which resulted in a partial response. Although pembrolizumab was initiated as maintenance therapy, it was not effective. Amrubicin was given as third‐line therapy, and stable disease was achieved without serious adverse effect for 6 months.ConclusionAlthough there is no established treatment for metastatic small cell bladder cancer, the current case report suggests the effectiveness of amrubicin in this setting.

show abstract

“…Typically, these two drugs are given one after the other on the same day. The combination of these drugs is highly effective and well tolerated in advanced thymoma, small cell lung cancer, testicular cancer, germ cell tumours [11][12][13]. Cisplatin is classified as an alkylating agent.…”

Section: Introductionmentioning

confidence: 99%

2,4-dinitrophenol enhances cisplatin and etoposide cytotoxic activity on prostate cancer cell line

Adamczuk,

Humeniuk,

Adamczuk

et al. 2023

Ann Agric Environ Med.

View full text Add to dashboard Cite

Introduction.Including additional compounds that disturb the energy metabolism of cancer cells in advanced cancer therapy regimens may be an approach to overcome the problem of drug resistance and the therapeutic effectiveness of classic chemotherapeutics. One of the compounds that decouple oxidative phosphorylation, and thus alter the activity of energy-producing pathways, is 2,4-DNP (2,4-dinitrophenol).Objective. The aim of the study was to assess the ability of the 2,4-DNP to sensitize prostate cancer cells to the action of cisplatin and etoposide, or to intensify their action. Materials and method. The research was carried out on three prostate cancer cell lines (LNCaP, PC-3, DU-145. To assess the effect of cisplatin or etoposide with 2,4-DNP on prostate cancer cells, MTT assay, analysis of the cell cycle and apoptosis detection was performed. Oxidative stress was investigated by CellRox fluorescence staining and expression of genes related to antioxidant defence. In addition, analysis was conducted of the expression of genes related to cell cycle inhibition, transporters associated with multi-drug resistance and DNA repair.Results. The study showed that the simultaneous incubation of 2,4-DNP with cisplatin or etoposide enhances the cytotoxic effect of the chemotherapeutic agent only in LNCaP cells (oxidative phenotype). Conclusions. The enhanced cytotoxic effect of chemotherapeutics by 2,4-DNP may be the result of disturbed redox balance, reduced ability of cells to repair DNA, and the oxidative metabolic phenotype of prostate cancer cells.

show abstract

Comparison of the second-line treatments for patients with small cell lung cancer sensitive to previous platinum-based chemotherapy: A systematic review and Bayesian network analysis

Cited by 4 publications

References 47 publications

Comparison of Efficacy and Safety between Carboplatin-Etoposide and Cisplatin-Etoposide Combination Therapy in Patients with Advanced Neuroendocrine Carcinoma: A Retrospective Study

Comparison of Efficacy and Safety between Carboplatin-Etoposide and Cisplatin-Etoposide Combination Therapy in Patients with Advanced Neuroendocrine Carcinoma: A Retrospective Study

Metastatic small cell bladder cancer treated with sequential systemic therapy including pembrolizumab and amrubicin: A case report

2,4-dinitrophenol enhances cisplatin and etoposide cytotoxic activity on prostate cancer cell line

Contact Info

Product

Resources

About